Search

International audience; Polymer nanoparticles (NPs) are extensively studied as drug delivery systems for various therapeutic indications, including drug and imaging agent delivery to the brain. Despite intensive research, their toxicological profile has yet to be fully characterized. In particular, the more subtle effects of nanomaterials on inflammatory processes have scarcely been investigated. Surface properties of NPs are amongst parameters governing interactions between living cells and NPs. They could considerably influence the toxicity and inflammatory response of the cells exposed to NPs.Polymeric NPs investigated here present a core-shell structure. The core is constituted of hydrophobic poly(lactic acid) (PLA) block and the surface is composed of a shell of hydrophilic block of polyethylene glycol (PEG). The effect of PEG chain length coating on the expression of genes involved in the inflammation response was investigated in two vascular endothelial cell lines (bEnd.3 and HUVEC) by qPCR. Moreover, ROS generation following NP uptake was evaluated. PEGylated NPs induce a mild and transient activation of inflammatory cytokine and chemokine genes. However, differences in PEG chain length did not show any significant effect on cytokine and chemokine gene expression and PEGylated NPs did not trigger ROS generation. The present results could contribute significantly to a deeper understanding of nanomaterial interactions and toxicity with vascular endothelial cells, guiding scientists in material coating choices.

Preparation of sophisticated delivery systems for nanomedicine applications generally involve multi-step procedures using organic solvents. In this study, we have developed a simple self-assembling process to prepare docetaxel-loaded hyaluronic acid (HA) nanocapsules by using a self-emulsification process without the need of organic solvents, heat or high shear forces. These nanocapsules, which comprise an oily core and a shell consisting of an assembly of surfactants and hydrophobically modified HA, have a mean size of 130 nm, a zeta potential of −20 mV, and exhibit high docetaxel encapsulation efficiency. The nanocapsules exhibited an adequate stability in plasma. Furthermore, in vitro studies performed using A549 lung cancer cells, showed effective intracellular delivery of docetaxel. On the other hand, blank nanocapsules showed very low cytotoxicity. Overall, these results highlight the potential of self-emulsifying HA nanocapsules for intracellular drug delivery. The authors acknowledge financial support from Xunta de Galicia (Competitive Reference Groups-FEDER Funds GRC2013-043). A. Cadete acknowledges her doctoral fellowship from the European Commission (EACEA) under the Nanofar program, Erasmus Mundus Joint Doctorate (EMJD). A. Olivera acknowledges her doctoral fellowship from the Spanish Ministry of Science, Innovation and Universities (grant number BES-2015-071236) SI

International audience; The use of neurotoxic chemical insecticides has led to consequences against the environment, insect resistances and side-effects on non-target organisms. In this context, we developed a novel strategy to optimize insecticide efficacy while reducing doses. It is based on nanoencapsulation of a pyrethroid insecticide, deltamethrin, used as synergistic agent, combined with a non-encapsulated oxadiazine (indoxacarb). In this case, the synergistic agent is used to increase insecticide efficacy by activation of calcium-dependant intracellular signaling pathways involved in the regulation of the membrane target of insecticides. In contrast to permethrin (pyrethroid type I), we report that deltamethrin (pyrethroid type II) produces an increase in intracellular calcium concentration in insect neurons through the reverse Na/Ca exchanger. The resulting intracellular calcium rise rendered voltage gated sodium channels more sensitive to lower concentration of the indoxacarb metabolite DCJW. Based on these findings, in vivo studies were performed on the cockroach Periplaneta americana and mortality rates were measured at 24 h, 48 h and 72 h after treatments. Comparative studies of the toxicity between indoxacarb alone and indoxacarb combined with deltamethrin or nanoencapsulated deltamethrin (LNC-deltamethrin), indicated that LNC-deltamethrin potentiated the effect of indoxacarb. We also demonstrated that nanoencapsulation protected deltamethrin from esterase-induced enzymatic degradation and led to optimize indoxacarb efficacy while reducing doses. Moreover, our results clearly showed the benefit of using LNC-deltamethrin rather than piperonyl butoxide and deltamethrin in combination commonly used in formulation. This innovative strategy offers promise for increasing insecticide efficacy while reducing both doses and side effects on non-target organisms.

Nanoparticle-loaded hydrogels are attractive pharmaceutical drug delivery systems that combine the advantages of both hydrogel (local administration and/or sustained drug release) and nanoparticle (stealthiness, targeting and decreased toxicity). The design of nanoparticle-loaded hydrogels is largely conventional, consisting of the dispersion of nanoparticles in a natural or synthetic polymer matrix to form a gel network. Novel nanoparticle-loaded hydrogels architecture could provide advantages in terms of innovation and application. We focused on the development of lipid nanocapsule (LNC)-based hydrogels without the use of a polymer matrix as a platform for drug delivery. Cytidine was modified by grafting palmitoyl chains (CytC16) and the new entity was added during the LNC phase-inversion formulation process allowing spontaneous gelation. Positioned at the oil/water interface, CytC16 acts as a crosslinking agent between LNCs. Association of the LNCs in a three-dimensional network led to the formation of polymer-free hydrogels. The viscoelastic properties of the LNC-based hydrogels depended on the LNC concentration and CytC16 loading but were not affected by the LNC size distribution. The LNC and drug-release profiles were controlled by the mechanical properties of the LNC-based hydrogels (slower release profiles correlated with higher viscoelasticity). Finally, the subcutaneous administration of LNC-based hydrogels led to classic inflammatory reactions of the foreign body-reaction type due to the endogenous character of CytC16, shown by cellular viability assays. New-generation nanoparticle-loaded hydrogels (LNC-based polymer-free hydrogels) show promise as implants for pharmaceutical applications. Once LNC release is completed, no gel matrix remains at the injection site, minimizing the additional toxicity due to the persistence of polymeric implants. Sustained drug-release profiles can be controlled by the mechanical properties of the hydrogels and could be tailor-made, depending on the therapeutic strategy chosen.

Purpose Current preclinical therapeutic strategies involving nanomedicine require increasingly sophisticated nanosystems and the characterization of the complexity of such nanoassemblies is becoming a major issue. Accurate characterization is often the factor that can accelerate the translational approaches of nanomedicines and their pharmaceutical development to reach the clinic faster. We conducted a case study involving the adsorption of the NFL-TBS.40–63 (NFL) peptide (derived from neurofilaments) to the surface of lipid nanocapsules (LNCs) (a combined nanosystem used to target glioblastoma cells) to develop an analytical approach combining the separation and the quantification in a single step, leading to the characterization of the proportion of free peptide and thus the proportion of peptide adsorbed to the lipid nanocapsule surface. Methods LNC suspensions, NFL peptide solution and LNC/NFL peptide mixtures were characterized using a Size-Exclusion Chromatography method (with a chromatographic apparatus). In addition, this method was compared to centrifugal-filtration devices, currently used in literature for this case study. Results Combining the steps for separation and characterization in one single sequence improved the accuracy and robustness of the data and led to reproducible results. Moreover the data deviation observed for the centrifugal-filtration devices demonstrated the limits for this increasingly used characterization approach, explained by the poor separation quality and highlighting the importance for the method optimization. The high potential of the technique was shown, proving that H-bond and/or electrostatic interactions mediate adsorption of the NFL peptide to the surface of LNCs. Conclusions Used only as a characterization tool, the process using chromatographic apparatus is less time and solvent consuming than classical Size-Exclusion Chromatography columns only used for separation. It could be a promising tool for the scientific community for characterizing the interactions of other combinations of nanosystems and active biological agents. Graphical abstract Supplementary Information The online version contains supplementary material available at 10.1007/s11095-021-03034-8.

Complexities surrounding the manufacture and quality control of nanomedicines become increasingly apparent. This research article offers a case study to investigate how, at the laboratory scale, various stages of liposome and nanoparticle synthesis affect the amount of residual solvent found in the formulations. The objective is to bring insights on the reliability of each of these processes to provide final products which meet regulatory standards and facilitate identifying possible bottleneck early during the development process. The residual solvent at various stages of preparation and purification was measured by headspace gas chromatography. Liposomes were prepared by two different methods with and without solvent. Polymer nanoparticles prepared via nanoprecipitation and purified by ultrafiltration were studied. The effects of purification by size exclusion chromatography and dialysis were also investigated. The complete removal of residual solvent requires processes which go beyond usual preparation methods. This work might prove valuable as a reference for scientists of different fields to compare their own practices and streamline the translation of nanomedicines into efficacious and safe drug products.

Hypothesis Prilling process is one of advanced techniques for manufacturing microspheres of controlled and uniform size. In this process, homogenous polymer droplets fall into an extraction medium. The aim of this study was to identify the key parameters influencing the behavior of PLGA polymer-based droplets falling into a complex extraction medium, to select appropriate conditions for prilling. Experiments Polymer solutions and extraction media were characterized by determining their viscosity, density and surface tension. A simple model simulating the prilling process was developed to study droplet behavior. Particle shape and velocity at the air-liquid interface and during sedimentation in the container were analyzed step by step. The correlations between the variables studied were visualized by principal component analysis (PCA). Findings Droplet deformation at the interface greatly affected the recovery and final particle shape. It depended on the viscosity ratio of polymer solution/extraction medium. The particle shape recovery depended on the viscosity and density of extraction media and polymer solutions. The solidification speed is also an important parameter. In media which the solvent diffused slowly, particles were able to relax and recover their shape, however, they can also deform during sedimentation and collision with the bottom of the cuvette.

L’invention concerne donc un procédé continu de nano-émulsification caractérisé en ce que ledit procédé est réalisé par inversion de phase en concentration (IPC) en réacteur microfluidique, et comprenant les étapes suivantes :a.injection dans un premier microcanal d’une phase aqueuse, ledit premier microcanal débouchant dans une chambre de formulation,b. injection dans un deuxième microcanal d’une phase grasse comprenant un ou plusieurs corps gras, et un ou plusieurs tensioactifs, ledit deuxième microcanal débouchant dans ladite chambre de formulation, puisc.mélange de la phase aqueuse et de la phase grasse dans ladite chambre de formulation, puisd. récupération, en sortie de la chambre de formulation, d’une suspension comprenant des nanocapsules.Dans un mode de réalisation, le ou les tensioactifs sont choisis parmi les tensioactifs hydrophiles non-ioniques, et leurs mélanges. Dans un mode de réalisation, le ou les tensioactifs sont choisis parmi les mono- et les di-esters d’acide gras et de polyéthylène glycol, et leurs mélanges. Dans un mode de réalisation, le ou les tensioactifs sont choisis parmi les mono- et les di-esters d’acide stéarique et de polyéthylène glycol, et leurs mélanges.Dans un mode de réalisation, le ou les corps gras sont choisis parmi les mono-esters, di-esters et tri-esters de glycérol, les mono-esters et di-ester de polyéthylène glycol, et leurs mélanges. Dans un mode de réalisation, le ou les corps gras sont choisis parmi les triglycérides en C8-C18, et leurs mélanges. Dans un mode de réalisation, le ou les corps gras sont choisis parmi les triglycérides des acides capriques et capryliques et leurs mélanges.Dans un mode de réalisation, la phase grasse comprend en outre un ou plusieurs co-tensioactifs. Dans un mode de réalisation, la phase grasse comprend en outre un ou plusieurs co-tensioactifs choisis parmi les tensioactifs non-ioniques. Dans un mode de réalisation, la phase grasse comprend en outre un ou plusieurs co-tensioactifs choisis parmi le monooléate de sorbitane ou le mono-éthyl éther de diéthylène glycol et leurs mélanges.Dans un mode de réalisation, le rapport pondéral de la somme des débits de tensioactifs et de co-tensioactifs sur le débit de corps gras dans la chambre de formulation est compris entre 0,8 et 4. Dans un mode de réalisation, le rapport pondéral de la somme des débits de tensioactifs et de co-tensioactifs sur le débit de corps gras dans la chambre de formulation est compris entre 2 et 4.Dans un mode de réalisation, le rapport pondéral de la somme des débits de tensioactif, de co-tensioactifs et de corps gras sur le débit de la phase aqueuse dans la chambre de formulation est compris entre 0,03 et 0,3. Dans un mode de réalisation, le rapport pondéral de la somme des débits de tensioactif, de co-tensioactifs et de corps gras sur le débit de la phase aqueuse dans la chambre de formulation est compris entre 0,04 et 0,2.Dans un mode de réalisation, les nanocapsules ont une taille particulaire comprise entre 15 et 120 nm. Dans un mode de réalisation, les nanocapsules ont une taille particulaire comprise entre 15 et 70 nm. Dans un mode de réalisation, les nanocapsules ont une taille particulaire comprise entre 20 et 50 nm.Dans un mode de réalisation, la phase grasse comprend en outre de l’eau, dans une teneur comprise entre 0 % et 30 % en poids, par rapport au poids total de la phase grasse. Dans un mode de réalisation, la phase grasse comprend en outre de l’eau, dans une teneur comprise entre 0 % et 20 % en poids, par rapport au poids total de la phase grasse. Dans un mode de réalisation, la phase grasse comprend en outre de l’eau, dans une teneur comprise entre 0 % et 15 % en poids, par rapport au poids total de la phase grasse.L’invention concerne également des nanocapsules susceptibles d’être obtenues par le procédé tel que décrit précédemment.L’invention concerne aussi l’utilisation des nanocapsules telles que décrites précédemment comme nanovecteurs de principe pharmaceutiquement actif.

Lauroyl-gemcitabine lipid nanocapsules (GemC12-LNC) hydrogel, administered intratumorally or perisurgically in the tumor resection cavity, increases animal survival in several orthotopic GBM models. We hypothesized that GemC12-LNC can be used as nanodelivery platform for other drugs, to obtain a combined local therapeutic approach for GBM. Paclitaxel (PTX) was selected as a model molecule and PTX-GemC12-LNC formulation was evaluated in terms of physicochemical and mechanical properties. The PTX-GemC12-LNC hydrogel stability and drug release were evaluated over time showing no significant differences compared to GemC12-LNC. The drug combination was evaluated on several GBM cell lines showing increased cytotoxic activity compared to the original formulation and synergy between PTX and GemC12. Our results suggest that GemC12-LNC hydrogel can be used as nanodelivery platform for dual drug delivery to encapsulate active agents with different mechanisms of action to achieve a better antitumor efficacy against GBM or other solid tumors.

Aim Anticancer drug-loaded hydrogels are a promising strategy for the local treatment of incurable brain tumors such as glioblastoma (GBM). Recently, we demonstrated the efficacy of lauroyl-gemcitabine lipid nanocapsule hydrogel (GemC12-LNC) in a U-87 MG xenograft orthotopic mouse model. In this study, we developed a reliable and reproducible surgical procedure to resect orthotopic GBM tumors in rats. GemC12-LNC hydrogel integrity was tested after brain administration in rats and its anti-tumor efficacy was tested on a 9L syngeneic orthotopic model. Results We demonstrated that LNC integrity is maintained at least for one week after local administration of GemC12-LNC. GemC12-LNC was able to delay the formation of recurrences in 9L tumor-bearing resected rats, demonstrating the efficacy of this nanomedicine hydrogel in this preclinical model. Conclusion Our results confirm that GemC12-LNC, a hydrogel uniquely formed by a nanocarrier and a cytotoxic drug, could be a promising and safe delivery tool for the local treatment of operable GBM tumors.

Gemcitabine is a nucleoside analog currently used for the treatment of various solid tumors as a single agent or in combination with other chemotherapeutic drugs. Its use against highly aggressive brain tumors (glioblastoma) has been evaluated in preclinical and clinical trials leading to controversial results. Gemcitabine can inhibit DNA chain elongation, is a potent radiosensitizer and it can enhance antitumor immune activity, but it also presents some drawbacks (e.g., short half-life, side effects, chemoresistance). The aim of this review is to discuss the challenges related to the use of gemcitabine for glioblastoma and to report recent studies that suggest overcoming these obstacles opening new perspectives for its use in the field (e.g., gemcitabine derivatives and/or nanomedicines).

The combination of pharmaceutical technologies can be a wise choice for developing innovative therapeutic strategies. The association of nanocarriers and gels provides new therapeutic possibilities due to the combined properties of the two technologies. Gels support the nanocarriers, localize their administration to the target tissue, and sustain their release. In addition to the properties afforded by the gel, nanocarriers can provide additional drug sustained release or different pharmacokinetic and biodistribution profiles than those from nanocarriers administered by the conventional route to improve the drug therapeutic index. This review focuses on recent (over the last ten years) in vivo data showing the advances and advantages of using nanocarrier-loaded gels. Liposomes, micelles, liquid and solid lipid nanocapsules, polymeric nanoparticles, dendrimers, and fullerenes are all nanotechnologies which have been recently assessed for medical applications, such as cancer therapy, the treatment of cutaneous and infectious diseases, anesthesia, the administration of antidepressants, and the treatment of unexpected diseases, such as alopecia.

Development of effective antibacterial agents for the treatment of infections caused by Gram-positive bacteria resistant to existing antibiotics, such as methicillin-resistant Staphylococcus aureus (MRSA), is an area of intensive research. In this work, the antibacterial efficacy of two antimicrobial peptides derived from plectasin, AP114 and AP138, used alone and in combination with monolaurin-lipid nanocapsules (ML-LNCs) was evaluated. Several interesting findings emerged from the present study. First, ML-LNCs and both plectasin derivatives showed potent activity against all 14 tested strains of S. aureus, independent of their resistance phenotype. Both peptides displayed a considerable adsorption (33%–62%) onto ML-LNCs without having an important impact on the particle properties such as size. The combinations of peptide with ML-LNC displayed synergistic effect against S. aureus, as confirmed by two methods: checkerboard and time-kill assays. This synergistic interaction enables a dose reduction and consequently decreases the risk of toxicity and has the potential of minimizing the development of resistance. Together, these results suggest that ML-LNCs loaded with a plectasin derivative may be a very promising drug delivery system for further development as a novel antibacterial agent against S. aureus, including MRSA.

International audience; Abstract The aim of the present study was to optimize the size and polydispersity of a lipid nanoemulsion as a function of the oil (Labrafac® WL1349), surfactant (Kolliphor® HS 15) and cosurfactant (Span® 80) phase composition and temperature. The nanoemulsions were prepared using a low-energy self-emulsification method. The Z-average diameter and the polydispersity index (PDI) were modeled with mixture experiments. Nanoemulsions from 20 nm to 120 nm with PDI < 0.2 were obtained at the three different tested temperatures (30 °C, 50 °C and 90 °C). The nanoemulsion size was able to be controlled with the oil, surfactant and cosurfactant concentrations. Interestingly, the smallest PDIs were obtained at 30 °C, and the cosurfactant concentration was able to be adjusted to optimize the formulation and to obtain nanoemulsions in the 20–120 nm range with a PDI smaller than 0.14. These nanoemulsions have shown a good stability at 4 °C in storage conditions and at 37 °C in diluted conditions.

Sterosomes (STEs), a new and promising non-phospholipidic liposome platform based on palmitic acid (PA) and cholesterol (Chol) mixtures, need to have polyethylene glycol (PEG) chains grafted to their surface in order to obtain long-circulating nanocarriers in the blood stream. A post-insertion method was chosen to achieve this modification. The post-insertion process of PEG-modified distearoylphosphoethanolamine (DSPE-PEG) was monitored using the zeta potential value of STEs. Various conditions including PEG chain length and the DSPE-PEG/PA-Chol ratio, were explored. Zeta potential of STEs changed from about −40 mV for non-modified STEs to values close to 0 mV by the end of the process, i.e. for PEG-modified STEs. The kinetics of DSPE-PEG insertion and the stability of the resulting PEG-modified STEs were not considerably influenced, within the investigated range, by changes in PEG chain lengths and in DSPE-PEG/PA-Chol proportion. The post-insertion of PEG chains reduced in vitro complement activation as well as in vitro macrophage uptake compared to the non-modified STEs. Moreover, longer blood circulation time in mice was established for PEG-modified STEs intravenously injected compared to non-modified STEs. These results establish that post-insertion process of PEG chains to STEs is a promising strategy for developing long-term circulating drug delivery nanocarriers. Fil: Cieślak, Anna. University Of Angers; Francia Fil: Wauthoz, Nathalie. University Of Angers; Francia. Université Libre de Bruxelles; Bélgica Fil: Nieto Orellana, Alejandro. University Of Angers; Francia Fil: Lautram, Nolwenn. University Of Angers; Francia Fil: Béjaud, Jérôme. University Of Angers; Francia Fil: Hureaux, José. University Of Angers; Francia Fil: Lafleur, Michel. University of Montreal; Canadá Fil: Benoit, Jean-Pierre. University Of Angers; Francia Fil: Salomon, Claudio Javier. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Química Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Química Rosario; Argentina Fil: Bastiat, Guillaume. University Of Angers; Francia

Organogels are semi-solid systems in which an organic liquid phase is immobilized by a 3-dimensional network composed of self-assembled gelator molecules. Although there is a large variety of organogel systems, relatively few have been investigated in the field of drug delivery, owing mostly to the lack of information on their biocompatibility and toxicity. In this work, organogelator-biocompatible structures based on aromatic amino acids, namely, tyrosine, tryptophan, and phenylalanine were synthesized by derivatization with aliphatic chains. Their ability to gel an injectable vegetable oil (i.e. safflower oil) and to sustain the release of a model anti-Alzheimer drug (i.e. rivastigmine) was then evaluated. Organogels and molecular packing were characterized by differential scanning calorimetry, rheology analysis, Fourier-transform infrared spectroscopy and X-ray crystallography. The amino acid derivatives were able to gel safflower oil through van der Waals interactions and H-bonds. Tyrosine-derivatives produced the strongest gels while tryptophan was associated with poor gelling properties. The superior gelling ability of tyrosine derivatives could be explained by their well-structured 2-dimensional packing in the network. The addition of an optimal N-methyl-2-pyrrolidone amount to tyrosine gels fluidized the network and allowed their injection through conventional needles. Upon contact with an aqueous medium, the gels formed in situ and released entrapped rivastigmine in a sustained fashion.

Gemcitabine, an anticancer agent which acts against a wide range of solid tumors, is known to be rapidly deaminated in blood to the inactive metabolite 2',2'-difluorodeoxyuridine and to be rapidly excreted by the urine. Moreover, many cancers develop resistance against this drug, such as loss of transporters and kinases responsible for the first phosphorylation step. To increase its therapeutic levels, gemcitabine is administered at high doses (1000 mg/m(2)) causing side effects (neutropenia, nausea, and so forth). To improve its metabolic stability and cytotoxic activity and to limit the phenomena of resistance many alternatives have emerged, such as the synthesis of prodrugs. Modifying an anticancer agent is not new; paclitaxel or ara-C has been subjected to such changes. This review summarizes the various chemical modifications that can be found in the 4-(N)- and 5'-positions of gemcitabine. They can provide (i) a protection against deamination, (ii) a better storage and (iii) a prolonged release in the cell, (iv) a possible use in the case of deoxycytidine kinase deficiency, and (v) transporter deficiency. These new gemcitabine-based sysems have the potential to improve the clinical outcome of a chemotherapy strategy.

With the goal of generating an efficient vector for systemic gene delivery, a new kind of nanocarrier consisting of lipid nanocapsules encapsulating DOTAP/DOPE lipoplexes (DNA LNCs) was pegylated by the post-insertion of amphiphilic and flexible polymers. The aim of this surface modification was to create a long-circulating vector, able to circulate in the blood stream and efficient in transfecting tumoral cells after passive targeting by enhanced permeability and retention effect (EPR effect). PEG conformation, electrostatic features, and hydrophylicity are known to be important factors able to influence the pharmacokinetic behaviour of vectors. In this context, the surface structure characteristics of the newly pegylated DNA LNCs were studied by measuring electrophoretic mobility as a function of ionic strength in order to establish a correlation between surface properties and in vivo performance of the vector. Finally, thanks to this PEGylation, gene expression was measured up to 84-fold higher in tumor compared to other tested organs after intravenous injection. The present results indicate that PEGylated DNA LNCs are promising carriers for an efficient cancer gene therapy.

Systems composed of a monoalkylated amphiphile and a sterol have been shown to form stable liquid-ordered (lo) lamellar phases; these include negatively charged mixtures of unprotonated palmitic acid/cholesterol (Chol) or cholesterol sulfate (Schol) and mixtures of positively charged cetylpyridinium chloride/Schol. Large unilamellar vesicles (LUVs) could be formed by these systems, using conventional extrusion methods. The passive permeability of these LUVs was drastically limited, a phenomenon associated with the high sterol content. In the present paper, we showed that octadecyl methyl sulfoxide (OMSO), a neutral monoalkylated amphiphile, can form, in the presence of cholesterol, LUVs that are stable at room temperature. Differential scanning calorimetry, infrared spectroscopy, and nuclear magnetic resonance spectroscopy of deuterium were used to characterize the phase behavior of OMSO/Chol mixtures. A temperature-composition diagram summarizing the behavior of the OMSO/Chol system is proposed; it includes a eutectic with an OMSO/Chol molar ratio of 5/5. It is found that the fluid phase observed at temperature higher than 43 degrees C is metastable at room temperature, and this situation allows extruding these mixtures to form stable LUVs at room temperature. This distinct behavior is associated with the strong H-bond capability of the sulfoxide group. The properties associated with this neutral formulation expand the potential of these non-phospholipid liposomes for applications in several areas such as drug delivery.

The phase behavior of mixtures formed with palmitic acid (PA) and one of the following sterols (dihydrocholesterol, ergosterol, 7-dehydrocholesterol, stigmasterol and stigmastanol), in a PA/sterol molar ratio of 3/7, has been characterized by IR and 2H NMR spectroscopy at different pH. Our study shows that it is possible to form liquid-ordered (lo) lamellar phases with these binary non-phospholipid mixtures. The characterization of alkyl chain dynamics of PA in these systems revealed the large ordering effect of the sterols. It was possible to extrude these systems, using standard extrusion techniques, to form large unilamellar vesicles (LUVs), except in the case of ergosterol-containing mixture. The resulting LUVs displayed a very limited passive permeability consistent with the high sterol concentration. In addition, the stability of these PA/sterol self-assembled bilayers was also found to be pH-sensitive, therefore, potentially useful as nanovectors. By examining different sterols, we could establish some correlations between the structure of these bilayers and their permeability properties. The structure of the side chain at C17 of the sterol appears to play a prime role in the mixing properties with fatty acid.

International audience; Growing tumor cell lines, such as U87-MG glioma cells, under mild hypoxia (3% O2) leads to a ca. 40% reduction in growth rate once implanted in the brain of nude mice, as compared to normoxia (21% O2) grown cells, wherein the former over-express HIF-1 and VEGF-A. Despite developing differently, the tumors have similar: blood perfusion, oxygen consumption, and vascular surface area parameters, whereas the number of blood vessels is nearly doubled in the tumor arising from normoxia cultured cells. Interestingly, tumor oxygen tension, measured using 19F-oximetry, showed that the normoxia grown cells led to tumors characterized by mild hypoxic environment (approximately 4%) conditions, whilst the hypoxia grown cells led to tumors characterized by physioxic environment (approximately 6%) conditions. This reversal in oxygen concentration may be responsible for the apparent paradoxical growth profiles.

International audience; Tumor-induced expansion of myeloid-derived suppressor cells (MDSCs) is known to impair the efficacy of cancer immunotherapy. Among pharmacological approaches for MDSC modulation, chemotherapy with selected drugs has a considerable interest due to the possibility of a rapid translation to the clinic. However, such approach is poorly selective and may be associated with dose-dependent toxicities. In the present study, we showed that lipid nanocapsules (LNCs) loaded with a lauroyl-modified form of gemcitabine (GemC12) efficiently target the monocytic MDSC subset. Subcutaneous administration of GemC12-loaded LNCs reduced the percentage of spleen and tumor-infiltrating M-MDSCs in lymphoma and melanoma-bearing mice, with enhanced efficacy when compared to free gemcitabine. Consistently, fluorochrome-labeled LNCs were preferentially uptaken by monocytic cells rather than by other immune cells, in both tumor-bearing mice and human blood samples from healthy donors and melanoma patients. Very low dose administration of GemC12-loaded LNCs attenuated tumor-associated immunosuppression and increased the efficacy of adoptive T cell therapy. Overall, our results show that GemC12-LNCs have monocyte-targeting properties that can be useful for immunomodulatory purposes, and unveil new possibilities for the exploitation of nanoparticulate drug formulations in cancer immunotherapy.

International audience; Medicines for the treatment of rare diseases frequently do not attract the interest of the pharmaceutical industry, and hospital pharmacists are thus often requested by physicians to prepare personalized medicines. Tuberous Sclerosis Complex (TSC) is a rare disease that causes disfiguring lesions named facial angiofibromas. Various topical formulations of rapamycin (=sirolimus) have been proved effective in treating these changes in small case series. The present study provides for the first time characterization of a 0.1% rapamycin cream formulation presenting good rapamycin solubilisation. The first step of the formulation is solubilisation of rapamycin in Transcutol®, and the second step is the incorporation of the mixture in an oil-in-water cream.A HPLC stability-indicating method was developed. Rapamycin concentration in the cream was tested by HPLC and confirmed that it remained above 95% of the initial concentration for at least 85 days, without characteristic degradation peaks. The preparation met European Pharmacopoeia microbial specifications throughout storage in aluminum tubes, including when patient use was simulated. Odour, appearance and colour of the preparation were assessed and no change was evidenced during storage. The rheological properties of the cream also remained stable throughout storage.To conclude, we report preparation of a novel cream formulation presenting satisfactory rapamycin solubilisation for the treatment of TSC cutaneous manifestations, with stability data. The cream is currently being used by our patients. Efficacy and tolerance will be reported later.

International audience; The local delivery of chemotherapeutic agents is a very promising strategy for the treatment of glioblastoma (GBM). Gemcitabine is a chemotherapeutic agent that has a different mechanism of action compared to alkylating agents and shows excellent radio-sensitizing properties. So, we developed an injectable gel-like nanodelivery system consisting in lipid nanocapsules loaded with anticancer prodrug lauroyl-gemcitabine (GemC12-LNC) in order to obtain a sustained and local delivery of this drug in the brain. In this study, the GemC12-LNC has been formulated and characterized and the viscoelastic properties of the hydrogel were evaluated after extrusion from 30G needles. This system showed a sustained and prolonged in vitro release of the drug over one month. GemC12 and the GemC12-LNC have shown increased in vitro cytotoxic activity on U-87 MG glioma cells compared to the parent hydrophilic drug. The GemC12-LNC hydrogel reduced significantly the size of a subcutaneous human GBM tumor model compared to the drug and short-term tolerability studies showed that this system is suitable for local treatment in the brain. In conclusion, this proof-of-concept study demonstrated the feasibility, safety and efficiency of the injectable GemC12-LNC hydrogel for the local treatment of GBM.

International audience; Release studies constitute a fundamental part of the nanovector characterization. However, it can be difficult to correctly assess the release of lipophilic compounds from lipid nanocarriers using conventional assays. Previously, we proposed a method including an extraction with oil to measure the loading stability of lipophilic dyes in lipid nanocapsules (LNCs). The method indicated a rapid release of Nile Red from LNCs, while the loading of lipophilic carbocyanine dyes remained stable. This method, although interesting for a rapid screening of the fluorescence labeling stability of nanocarriers, is far from what happens in vivo, where lipid acceptor phases are nanostructured. Here, lipophilic dye loading stability has been assessed, by monitoring dye transfer from LNCs toward stable colloidal lipid nanocompartments, i.e. non-loaded LNCs, using new methodology based on size exclusion chromatography (SEC) and Förster Resonance Energy Transfer (FRET). Dye transfer between LNCs and THP-1 cells (as model for circulating cells) has also been studied by FACS. The assays reveal an almost instantaneous transfer of Nile Red between LNCs, from LNCs to THP-1 cells, between THP-1 cells, and a reversal transfer from THP-1 cells to LNCs. On the contrary, there was no detectable transfer of the lipophilic carbocyanine dyes. Dye release was also analyzed using dialyses, which only revealed a very slow release of Nile Red from LNCs, demonstrating the weakness of membrane based assays for investigations of the lipophilic compound loading stability in lipid nanocarriers. These results highlight the importance of using relevant release assays, and the potential risk of an immediate unloading of lipophilic fluorescent dyes from lipid nanocarriers, in the presence of a lipid acceptor nanocompartment. Some misinterpretations of cellular trafficking and in vivo biodistribution of fluorescent nanoparticles should be avoided.

The purpose of this study is the assessment of gel technology based on a lauroyl derivative of gemcitabine encapsulated in lipid nanocapsules delivered subcutaneously or intravenously after dilution to (i) target lymph nodes, (ii) induce less systemic toxicity and (iii) combat mediastinal metastases from an orthotopic model of human, squamous, non-small-cell lung cancer Ma44-3 cells implanted in severe combined immunodeficiency mice. The gel technology mainly targeted lymph nodes as revealed by the biodistribution study. Moreover, the gel technology induced no significant myelosuppression (platelet count) in comparison with the control saline group, unlike the conventional intravenous gemcitabine hydrochloride treated group (P0.05). Besides, the gel technology, delivered subcutaneously twice a week, was able to combat locally mediastinal metastases from the orthotopic lung tumor and to significantly delay death (P0.05) as was the diluted gel technology delivered intravenously three times a week.Lung cancer is one of the leading causes of mortality worldwide. A significant proportion of patients with this disease have lymph node metastasis. In this study, the authors investigated the use of lipid nanocapsules, loaded with the lipophilic pro-drug gemcitabine for targeting tumors in lymph nodes after subcutaneous injection. This delivery method was shown to be effective in controlling tumor progression and may be useful in future clinical use.

Numéro spécial: Translational Nanomedicine; International audience; Patients diagnosed with an advanced-stage cancer present a dismal prognosis due to the presence of metastases. From the primary tumor, the cancer cells are disseminated via lymphatic circulation; metastases develop initially in lymph nodes. Therefore, the targeting of lymph nodes needs to be improved in the design of future chemotherapy, and one way to ensure this targeting is by using the subcutaneous (SC) route. Using lipid nanocapsules (LNCs) (40 nm and fluorescently-labeled with DiD) as nanocarriers, a correlation between the SC injection site (behind the neck, the right and left flanks, and above the tail) for LNC administration and specific lymph node accumulation (left and right cervical, axillary and inguinal lymph nodes) was achieved for Sprague-Dawley rats. The pharmacokinetic and biodistribution profiles confirmed the absence of LNCs in systemic circulation after SC administration due to the optimal size of the LNCs. With appropriate SC administration, LNCs can accumulate in specific lymph nodes, whereas IV administration led to a weak accumulation of LNCs in all lymph nodes. Specific accumulation followed the lymph flow: bottom-up from the lower to upper limbs and top down from the head, with two lymph circulation partitions: right upper limb and the rest. Administration above the tail presented high inguinal and axillary lymph node accumulation whereas weak accumulation was observed after administration behind the neck. LNCs administered in the left flank only accumulated in the left inguinal and axillary lymph nodes, whereas left and right inguinal and axillary lymph nodes presented accumulation after administration in the right flank. Cervical lymph nodes, in the opposite direction of lymph flow, were never targeted after SC administration, whatever the injection site.

Water soluble associative polymers based on polyacrylamide (PAM) grafted with short poly(propylene oxide) (PPO) chains as pendant groups were synthesized. Two different methods were used (1) homogeneous (water + acetonitrile) (2) micellar copolymerization, in the presence of sodium dodecyl sulphate (SDS) to solubilize the hydrophobic comonomer, PPO methacrylate (PPOMA). As expected from the literature, random or blocky distribution of PPO along the PAM chain, respectively, is obtained by these two methods. This work focuses on the characterization of the micellar reactional medium in order to have a good estimate of the length of the PPO sequences along the main chain. An extensive study of the mixture SDS/PPOMA was performed, by using fluorimetry, light scattering and conductimetry, to characterize the initial mixed micelles (critical micellar concentration and aggregation number). It is shown that the total aggregation number of the micelles and that of SDS decrease when the concentration of PPOMA increases. In addition, preliminary turbidimetry and viscosimetry studies of the thermo-associative properties of the two polymers are given.

Hypothesis Liposomes made of single-chain amphiphiles and a large amount of sterols display several advantages including a limited permeability. In the present paper, we examine the possibility to prepare such non-phospholipid liposomes with interfacial polyethylene glycol (PEG) in order to improve their circulation in the blood stream. Cholesterol (Chol) was chosen as the PEG anchor. Experiments The phase behavior of mixtures of palmitic acid (PA) and cholesterol including various proportions of PEGylated cholesterol (PEG-Chol) was characterized. In conditions leading to the formation of fluid bilayers, properties of the resulting liposomes were assessed. Findings Up to 20 mol% of PEGylated cholesterol could be introduced without significant perturbations in fluid bilayers made of PA and cholesterol. With 10 mol% PEG-Chol, PA/Chol/PEG-Chol liposomes showed a very limited permeability to calcein and doxorubicin. Doxorubicin could be actively loaded in PA/Chol/PEG-Chol liposomes with a high drug loading efficiency and a high drug to lipid ratio. Pharmaco-kinetic experiments in rats indicated that interfacial PEG reduced the clearance of PA/Chol liposomes compared to the naked ones. However the lifetime of these non-phospholipid liposomes in the blood circulation was considerably shorter than that observed for control PEGylated phospholipid liposomes, a phenomenon associated with the negative interfacial charge of the PA/Chol/PEG-Chol liposomes.

International audience; The challenge of tissue engineering of the infarcted heart is how to improve stem cell engraftment, survival, homing, and differentiation for myocardial repair. We here propose to integrate human adipose-derived stem cells (ADSCs) and pharmacologically active microcarriers (PAMs), a three-dimensional (3D) carrier of cells and growth factors, into an injectable hydrogel (HG), to obtain a system that stimulates the survival and/or differentiation of the grafted cells toward a cardiac phenotype. PAMs are biodegradable and non-cytotoxic poly(lactic-co-glycolic acid) (PLGA) microspheres conveying cells on their 3D surface that deliver continuously and in a controlled manner a growth factor (GF) acting on the transported cells and on the microenvironment to improve engraftment. The choice of the appropriate GF and its protection during the formulation process and delivery are essential. In this study two GFs, hepatocyte growth factor (HGF) and insulin-like growth factor (IGF-1), have been encapsulated under a solid state in order to limit their interaction with the polymer and conserve their integrity. GF precipitation conditions and release profile from PAMs have been first investigated before combining them to ADSCs. The released IGF-1 and HGF induced the protein synthesis of cardiac differentiation markers GATA4, Nkx2.5, cTnI and CX43 after 1 week in vitro. Moreover, the GFs accelerated cell cycle progression, as suggested by the increased expression of Cyclin D1 mRNA and the widespread distribution of Ki67 protein. Integrating PAMs within the thermosensitive P407 hydrogel increased their elastic properties but decreased the transcription of most cardiac markers. In contrast, CX43 expression increased in ADSC–PAM–GF complexes embedded within the hydrogel compared to the ADSCs cultured alone in the absence of P407. These results suggest that particulate scaffolds releasing HGF and IGF-1 may be beneficial for applications in tissue-engineering strategies for myocardial repair and the association with a P407 hydrogel can increase substrate elasticity and junction connections in ADSCs.

International audience; Small interfering RNA (siRNA)-mediated gene therapy is a promising strategy to temporarily inhibit the expression of proteins implicated in carcinogenesis or chemotherapy resistance. Although intra-tumoral administration can be envisaged, studies currently focus on formulating nanomedicines for intravenous injection to target tumor sites as well as metastases. The development of synthetic nanoparticles and liposomes has advanced greatly during the last decade. The objective of this work consists in formulating and optimizing the encapsulation of siRNA into lipid nanocapsules (LNCs) for efficient gene therapy to target melanoma cells. SiRNA LNCs were prepared from DOTAP/DOPE lipoplexes, and the siRNA amount and lipid/siRNA charge ratio were assayed to improve the stability and the encapsulation yield. Cryo-TEM imaging of the siRNA lipoplexes and LNC morphology revealed specific organization of the siRNA DOTAP/DOPE lipoplexes as well as specific lipid microstructures that can be eliminated by purification. No cytotoxicity of the siRNA LNCs against the melanoma SK-Mel28 cell line was observed at concentrations of up to 500 ng/mL siRNA. In vitro siRNA transfection experiments, compared to Oligofectamine (TM), demonstrated interesting targeted gene silencing effects. Finally, complement activation assays confirmed the feasibility of the PEGylation of siRNA LNCs as part of a passive targeting strategy for future in vivo melanoma-and metastasis-targeting experiments.

International audience; The assessment of tumor oxygenation is a crucial factor in cancer therapy and may be carried out using fluorine MRI once fluorine probes have been distributed within the tumor. However, the deposit of those highly fluorinated compounds often jeopardizes anatomical image quality and requires emulsification of the probes. Due to the high density and the high lipophilicity of perfluorocarbons, nanoemulsion of these molecules usually requires high-energy processes. In the present work, we discuss the synthesis and the physico-chemical characterization of perfluorocarbon nanocapsules using a low-energy phase-inversion process. The nanocapsules were tested on a mouse tumor brain model to assess oxygenation.

International audience; Numerous studies on nanocarriers use fluorescent dye labeling to investigate their biodistribution or cellular trafficking. However, when the fluorescence dye is not grafted to the nanocarrier, the question of the stability of the labeling arises. How can it be validated that the fluorescence observed during an experiment corresponds to the nanocarriers, and not to the free dye released from the nanocarriers? Studying the integrity of the labeling is challenging. Therefore, an innovative approach to confirm the labeling stability was developed, based on the transfer of a fluorescent dye from its hosting nanocarrier to a lipophilic compartment. Lipid nanocapsules (LNC) and triglyceride oil were used as models. The protocol involved mixing of LNC suspension and oil, and then separation by centrifugation. The quality of the separation was controlled by light scattering, using the derived count rate tool. Dye transfer from loaded LNCs to the lipophilic compartment or from a lipophilic compartment containing dye to non-loaded LNC was investigated by varying the nature of the dye and the oil, the oil volume and the LNC dilution. Tensiometry was used to define the dye location in the nanocarrier. Results showed that when dyes such as Nile Red and Coumarin-6 are located in oily core, the transfer occurred in a partition-dependent manner. In contrast, when the dye was entrapped in the surfactant shell of LNCs such as lipophilic indocarbocyanines (i.e. DiO, DiI and DiD), no transfer was observed. Dye diffusion was also observed in cell culture, with Nile Red inside lipid bodies of HEI-OC1 cells, without uptake of LNCs. In contrast, DiO-loaded LNCs had to be internalized to observe fluorescence inside the cells, providing a further confirmation of the absence of transfer in this case, and the stability of fluorescence labeling of the LNCs.

International audience; Attachment of polysaccharides on the surface of nanoparticles offers possibility to modify physicochemical and biological properties of the core particles. Surface of lipid nanocapsules (LNC) was modified by post-insertion of amphiphilic lipochitosan (LC) or lipodextran (LD). Modelling of these LNC by drop tensiometer technique revealed that the positively charged LC made the LNC surface more rigid whereas the neutral, higher M(W) LD had no effect on the surface elasticity. Both LNC-LC and LNC-LD activated more the complement system than the blank LNC, thus proposing increased capture by the mononuclear phagocyte system (MPS). In vitro, the positively charged LNC-LC were more efficiently bound by the model HEK293(β(3)) cells compared to LNC and LNC-LD. Finally, it was observed that neither LC nor LD did change in vivo biodistribution properties of LNC in mice. These polysaccharide-coated LNC, especially LNC-LC, are promising templates for targeting ligands (e.g. peptides, proteins) or therapeutic molecules (e.g. siRNA).

Over the past few decades, the development of nanomedicines has been significant with the discovery of new drugs, new targets and also new drug delivery systems. The link between nanotechnological development and medicine can provide medical and pharmaceutical benefits, particularly in the field of ...

In industrialized nations, sensorineural hearing loss is a common disease and is usually caused by a primary loss of auditory hair cells, which are the inner ear’s sensory cells. In addition to hereditary factors, acquired causes, such as increased noise exposure or the application of ototoxic drugs, play a crucial role in the development of sensorineural hearing loss.1,2 An effective treatment for damaged hair cells or for the regeneration of already degenerated sensory cells of the inner ear in humans is not yet possible. Instead, the prosthetic forms of therapy are performed to replace the damaged organ’s function. Severely impaired and deaf patients are treated by implantation of electronic inner ear prostheses called cochlear implants. Deaf patients treated with cochlear implants gain a renewed sense of hearing and have a greater opportunity to communicate using audible speech.3 This leads to improved social integration and a significant increase in the patient’s quality of life. Cochlear implants use a multichannel electrode that is inserted into the scala tympani to replace the function of the missing hair cells. Through the formation and transmission of spiral ganglion cell (SGC) action potentials, an artificially-generated sound impression is achievable. However, following the primary loss of hair cells, a progressive decrease in SGC density is observed.4 This is caused by missing electrical and neurotrophic stimulation, as well as other forms of stimulation.5,6 To achieve better speech recognition with cochlear implants, a high number of SGC must be ensured.6 A large number of neurotrophic factors have a protective effect on SGC after primary hair cell loss. The systemic treatment of inner ear diseases is complicated by the presence of the blood–cochlear barrier. Adequate drug levels are only reached through the application of very high drug doses, which leads to an increased risk of side effects. Through local application of neurotrophic factors, the progressive degeneration of SGC may be decreased. Important representatives of this substance group are brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor, and fibroblast growth factor.7,8 Nevertheless, continuous therapy is necessary because previous studies detected a progressive reduction of SGC after the cessation of therapeutical application of BDNF.9 The first attempts to produce continuous drug-delivery systems were realized using osmotic pumps. These pumps allowed continuous application periods into the inner ear for weeks. Because of delivery time limitations and the necessity of pump changes that would allow for longer application duration, this approach is not feasible for human therapeutic applications. Another option for chronic neurotrophic treatment is gene therapy. By introducing the gene sequences of neurotrophic factors to the cellular nucleus, the transfected cells may provide a sustainable endogenous production of neuroprotective substances.10,11 Via viral gene transfer, these factors were already implemented in the inner ear, although an expression of the introduced sequences did not demonstrate cell-specific gene transfer.12,13 Furthermore, only a temporary expression of about 3 weeks was achieved, which is not desirable in terms of long-term therapy.14 In addition, the use of viral vectors has considerable disadvantages, such as potential infection and the ability to trigger inflammatory or immunological processes.15 In addition to the viral vectors, artificially manufactured nanoparticles offer a promising ability to transport drugs and gene sequences with the ability of cargo release over a long period of time. Today, a variety of manufactured nanoparticles, which consist of organic and inorganic parts, can be assembled. In addition to their common uses in industry, a wide range of applications in health and medicine are achievable using nanoparticles.16 The advantages of nanoparticles are the impossibility of infection and the production of biodegradable scaffolds, for which a low response of the immune system is expected. Furthermore, nanoparticles can be produced inexpensively. By considering the property of the production of biological building principles, nanoparticles are ideal for the transport of medical drugs or genes. In addition to the transport function, it is possible to modify the surface of nanoparticles with specific receptors so that they will selectively bind to specific cells. The use of nanoparticles as a targeted treatment of specific cell populations results in a significant reduction of side effects.16 Recent research proved that fluoresceine-5-isothiocyanate (FITC)-labeled lipidic nanocapsules (LNC), locally inserted into the scala tympani of guinea pigs, infiltrated cell populations of the inner ear without causing functional or anatomical damage. 17 Those data were the first to demonstrate the ability of drug-unloaded LNC to enter inner ear cells. However, LNC-mediated drug delivery was not examined in that study. Besides the density of healthy SGC, the optimal effectiveness of cochlear implants is influenced by another important factor. In the postoperative onset of foreign body reaction, the organism encapsulates the implant through the production of fibrous tissue growth. This results in decreased nerve– electrode interaction, increased spread of neuronal excitation, reduced frequency selectivity, and increased impedances.18 Rolipram, an intracellular-acting phosphodiesterase-4 inhibitor, showed neuroprotective properties in former studies.19,20 Furthermore, anti-inflammatory effects have also been proven in animal models.21 We hypothesize that rolipram can potentially protect SGCs and reduce inflammatory reactions. If applied systemically, intravenously, or orally, rolipram has a bioavailability of 74%–77%.22 However, due to the blood–brain barrier, systemically-applied drugs that are used for inner ear treatment must be administered in such high dosages to have a biological effect on their target cells in the inner ear, that side effects may occur. To avoid massive side effects, local treatment of the inner ear is favored. In order to decrease the drugs applied locally to the inner ear, a targeted drug delivery is preferable. By encapsulating rolipram into a vehicle, such as LNC, a targeted drug delivery may be realized in the future. This will decrease the amount of drugs that are needed for human therapy. In the inner ear, a targeted drug delivery will lead to a significant dosage reduction and, as a result, to a lower risk of side effects when compared to systemic treatment. Additionally, the lower dose is also economically beneficial. We hypothesize that LNC provide a feasible drug-delivery system that can be used to transport rolipram into the cytoplasm. Once in the cytoplasm, rolipram will be released and induce its biological effects. This study examines the effect of rolipram and rolipram encapsulated in LNC on the survival rate, soma diameter, and neurite length of neonatally-harvested SGC in order to determine whether the drug’s effect is increased using LNC as a drug-delivery system. Furthermore, the effect of rolipram and the combination of LNC and rolipram is evaluated on the tumor necrosis factor-α (TNF-α) secretion of lipopolysaccharide (LPS)- stimulated dendritic cells (DC). This experiment indirectly provides information about the release of the payload and may demonstrate the potential of LNC as a delivery system for rolipram. Additionally, the results provide further insight into the anti-inflammatory effect of rolipram. This effect is due to the key role that TNF-α plays in the proinflammatory processes, which is appreciable in reducing postoperative reactions on cochlear implants. Based on in vitro results, we performed experiments on systemically deafened guinea pigs in order to examine LNC’s suitability for rolipram delivery in vivo.

Deformability of nanoparticles might affect their behaviour at biological interfaces. Lipid nanocapsules (LNCs) are semi-solid particles resembling a hybrid of polymer nanoparticles and liposomes. Deformability of LNCs of different sizes was modelled by drop tensiometer technique. Two purification methods, dialysis and tangential flow filtration (TFF), were applied to study experimental behaviour and deformability of LNCs in order to evaluate if these properties contributed to membrane passing. Rheological parameters obtained from the drop tensiometer analysis suggested decreasing surface deformability of LNCs with increase in diameter. Dialysis results showed that up to 10% of LNCs can be lost during the process (e.g. membrane accumulation) but no clear evidence of the membrane passing was observed. Instead, LNCs with initial size and size distribution could be found in the TFF filtrate although molecular weight cut-off (MWCO) of the membrane used was smaller than the LNC diameter.

International audience; The aim of this study was to unravel, by focusing on cell surface properties, the underlying virulence factors contributing to the difference in the pathogenicity observed in two Acinetobacter baumannii strains isolated from the same patient. The two strains were phenotypically different: (i) a mucoid strain (AB-M), highly virulent in a mouse model of pneumonia, and (ii) a nonmucoid strain (AB-NM), moderately virulent in the same model. The study of the cell surface properties included the microbial adhesion to solvents method, the measurement of the electrophoretic mobility of bacteria, the analysis of biofilm formation by calcofluor white staining, the adherence to silicone catheters, and scanning electron microscopy. The AB-NM strain was more hydrophobic, more adherent to silicone catheters, and produced more biofilm than the AB-M strain. Scanning electron microscopy showed bacterial cells with a rough surface and the formation of large cell clusters for AB-NM whereas the AB-M strain had a smooth surfa..., Le but de cette etude était d’étudier, en se focalisant sur les propriétés de surface des bactéries, des caractères potentiellement impliqués dans la différence de pouvoir pathogène de deux souches d’Acinetobacter baumannii isolées chez un même patient. Ces souches étaient phénotypiquement différentes : une souche mucoïde (AB-M) caractérisée par un pouvoir pathogène élevé dans un modèle expérimental murin de pneumopathie, et une souche non mucoïde (AB-NM), plus faiblement pathogène dans le même modèle. L’étude des propriétés de surface a utilisé la méthode d’adhésion des bactéries aux solvants, la mesure de la mobilité électrophorétique des bactéries, l’analyse de la formation de biofilm par marquage au calcofluor, l’adhésion à des cathéters en silicone, et la microscopie électronique à balayage. La souche AB-NM est apparue plus hydrophobe, plus adhérente aux cathéters, et plus productrice de biofilm que la souche AB-M. L’observation en microscopie électronique à balayage a montré des bactéries à surface ...

International audience

Lipidic NanoCapsules (LNCs) were prepared via an emulsion phase inversion method. Nanoparticles with hydrodynamic diameter of 25, 50 and 100 nm were easily obtained. Their surfaces are covered with short PEG chains (PEG 660) which are not bearing any chemical reactivities. Thus, in order to overcome this handicap towards post-functionalization possibilities, post-insertion of DSPE-PEG2000 amino (DSPA) can be employed. In order to characterize the insertion step, we have developed a chemical assay for the quantification of amino group inside the PEG shell of LNCs. Subsequently, the post-insertion yield was found to be comprised between 60 and 90% whatever the hydrodynamic diameter of the LNCs is. By means of simple calculations, the density of amino group is estimated to be closed to 0.2 and 1.2 molecules/nm(2). The formulation of LNCs and their controlled functionalization represent an interesting system for the development of bionanoconjugates in a short and effective process.

Organogels can be prepared by immobilizing an organic phase into a threedimensional network coming from the self-assembly of a low molecular weight gelator molecule. In this work, an injectable subcutaneous organogel system based on safflower oil and a modified-tyrosine organogelator was evaluated in vivo for the delivery of rivastigmine, an acetylcholinesterase (AChE) inhibitor used in the treatment of Alzheimer’s disease. Different implant formulations were injected and the plasmatic drug concentration was assayed for up to 35 days. In parallel, the inhibition of AChE in different brain sections and the biocompatibility of the implants were monitored. The pharmacokinetic profiles were found to be influenced by the gel composition, injected dose and volume of the implant. The sustained delivery of rivastigmine was accompanied by a significant prolonged inhibition of AChE in the hippocampus, a brain structure involved in memory. The implant induced only a minimal to mild chronic inflammation and fibrosis, which was comparable to poly(D,L-lactide-co-glycolide) in situ-forming implants. These findings suggest that tyrosine-based organogels could represent an alternative approach to current formulations for the sustained delivery of cholinesterase inhibitors., Faculté de Pharmacie

The phase behavior of mixtures formed by palmitic acid (PA), cholesterol (Chol), and sodium cholesteryl sulfate (Schol) has been characterized by differential scanning calorimetry and infrared and 2H NMR spectroscopy. It is reported that it is possible to form, with PA/sterol mixtures, fluid lamellar phases where the sterol content is very high (a sterol mole fraction of 0.7). As a consequence of the rigidifying ability of the sterols, the PA acyl chains are very ordered. The stability of these self-assembled bilayers is found to be pH-dependent. This property can be controlled by the Chol/Schol molar ratio, and it is proposed that this parameter modulates the balance between the intermolecular interactions between the constituting species. A phase-composition diagram summarizing the behavior of these mixtures as a function of pH, at room temperature, is presented. It is also shown that it is possible to produce large unilamellar vesicles (LUVs) from these mixtures, using standard extrusion techniques. The resulting LUVs display a very limited passive release of the entrapped material. In addition, these LUVs constitute a versatile vector for pH-triggered release.

International audience; We present a novel formulation of non-phospholipid liposomes formed from cholesterol and palmitic acid. Despite the fact that these two lipidic species do not form individually fluid bilayers, we show that once mixed together, fluid bilayers can be obtained and, moreover, these can be extruded using classical extrusion processes to form liposomes. The chemical analysis indicates that these liposomes contain 70 mol % cholesterol, a content that is considerably higher that the saturation limit generally reported for phospholipid bilayers. These cholesterol-rich liposomes, formed with molecules that have low toxicity in vivo, display an improved impermeability relative to that of traditional phospholipid liposomes. In addition, because of the presence of palmitic acid, the stability of the liposomes is pH-dependent, and it is possible to trigger the release of encapsulated materials by pH stimuli.

To provide a simplified dosing schedule and potentially reduce side effects associated to peak plasma concentrations, an in situ-forming oleogel implant was studied for the sustained-release of rivastigmine.The gel was prepared by dissolving 5-10% (w/w) N-stearoyl L: -alanine methyl ester (SAM) organogelator in safflower oil containing either dissolved rivastigmine or its dispersed hydrogen tartrate salt. Rheological analysis, differential scanning calorimetry, and infrared spectroscopy were carried out to assess the impact of drug incorporation on the oleogel; this was followed by in vitro and in vivo release studies.A weakening of intermolecular interactions was suggested by gel-sol transition temperature drops of 10-15 degrees C upon incorporation of dissolved drug. Meanwhile, the dispersed drug salt induced minimal or no changes in transition temperature. Gels containing dispersed rivastigmine had the lowest burst in vitro (15% in 24 h). In vivo, the 10% SAM formulation containing dispersed rivastigmine provided prolonged drug release within the therapeutic range for 11 days, with peak plasma levels well below the toxic threshold and up to five times lower than for the control formulation.This study established SAM gels to be a promising option for sustained-release formulations in the treatment of Alzheimer's Disease.